Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Open-label Study of IGSC 20% in Japanese Patients with Primary Immunodeficiency Disease
jRCT2080225067Phase 3Completed
- Sponsor
- Takeda
- Start
- Feb 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of human normal immunoglobulin in Immunogenetic disorder and Primary antibody deficiency (PAD) (3 arms), sponsored by Takeda. Primary endpoints: Pharmacokinetics of IGSC 20%, Safety and tolerability of IGSC 20% and 1 more. Started Feb 2020; status: completed.
02
Drugs
human normal immunoglobulin
03
Conditions
Immunogenetic disorderPrimary antibody deficiency (PAD)
Beyond the preview
Go deeper on jRCT2080225067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225067.